Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2018-12-12 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于收到公司实际控制人提议回购公司股份的函的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from a company regarding a proposal by its actual controller to repurchase company shares. It details the proposed share buyback price, total funds to be used, and the intended use of repurchased shares for employee stock plans. The document includes no financial statements or detailed financial data but focuses on the share repurchase plan and related procedural information. This fits the definition of a Transaction in Own Shares (POS) filing, which covers announcements of share buybacks or sales of own shares. The document length is short and it is not a report or a notice of report publication, so it is not RPA or RNS. Therefore, the correct classification is POS with high confidence.
2018-12-12 Chinese
关于回购公司股份的预案
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding a company's plan to repurchase its own shares, including the purpose, amount, price, method, authorization, and risk factors. It discusses the board and shareholder approvals required, the financial impact, and legal compliance. The content focuses on the share buyback plan and its implementation rather than financial results or earnings. It is not a full financial report, earnings release, or management discussion. It is not a regulatory certification or a simple announcement of a report publication. The document fits the definition of a Transaction in Own Shares (POS) filing, which covers company announcements about share repurchase activities.
2018-12-12 Chinese
2018年第一期员工持股计划（草案）摘要
Regulatory Filings Classification · 95% confidence The document is a detailed draft of an employee stock ownership plan (员工持股计划草案) for 瑞康医药集团股份有限公司. It includes comprehensive information about the plan's legal basis, participants, funding, stock sources, management structure, rights and obligations of participants, asset management, and procedures for approval and implementation. The document is lengthy (over 14,000 characters) and contains no financial statements or earnings data. It is not an announcement of a report but the actual plan draft itself. This type of document is a regulatory filing related to employee stock ownership plans and does not fit into categories like Annual Report, Earnings Release, or Capital/Financing Update. It is not a proxy solicitation or voting results announcement either. Given the nature of the document, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not neatly fit into other specific categories.
2018-12-12 Chinese
关于召开2018年第三次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2018 third extraordinary general meeting of shareholders for 瑞康医药集团股份有限公司. It includes information about the meeting time, location, agenda items (such as amendments to the company charter, share repurchase plans, and employee stock ownership plans), voting procedures, registration details, and proxy authorization forms. The content is focused on informing shareholders about the meeting logistics and agenda, not on reporting financial results or management commentary. It is not a report itself but a formal announcement and notice for a shareholders meeting. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2018-12-12 Chinese
第三届董事会第十七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 17th meeting of the third board of directors of 瑞康医药集团股份有限公司. It includes multiple board decisions such as amendments to the company charter, a share repurchase plan, an employee stock ownership plan, and authorization for the board to handle related matters. The document also mentions the need to submit these resolutions to the 2018 third extraordinary general meeting of shareholders for approval. The content focuses on board meeting decisions and corporate governance matters rather than financial results, audit opinions, or regulatory certifications. It is not a full annual or interim report, nor is it a simple announcement of a report publication. The document is primarily about board resolutions and management decisions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (3872 characters) and detailed voting results support this classification.
2018-12-12 Chinese
独立董事对第三届董事会第十七次会议相关事项的独立意见
Transaction in Own Shares Classification · 95% confidence The document is an independent directors' opinion on the company's board meeting matters, specifically regarding a share repurchase plan and an employee stock ownership plan. It references compliance with laws and regulations, the board's decision-making process, and the necessity and feasibility of the share repurchase. The document is a formal opinion letter from independent directors rather than a full report or announcement of financial results. It does not contain financial statements or detailed financial data but rather governance and compliance opinions related to capital actions. This fits best under the category of Transaction in Own Shares (POS), as it deals with the company's share repurchase plan and related employee stock plan, which are capital transactions involving the company's own shares.
2018-12-12 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.